Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

被引：22

作者：

Guglielmelli, P. ^{[1
,2
]}

Biamonte, F. ^{[1
,2
]}

Spolverini, A. ^{[1
,2
]}

Pieri, L. ^{[1
,2
]}

Isgro, A. ^{[3
]}

Antonioli, E. ^{[1
,2
]}

Pancrazzi, A. ^{[1
,2
]}

Bosi, A. ^{[1
,2
]}

Barosi, G. ^{[3
]}

Vannucchi, A. M. ^{[1
,2
]}

机构：

[1] Univ Florence, Dipartimento Area Crit, Unita Funz Ematol, Florence, Italy

[2] Ist Toscano Tumori, Florence, Italy

[3] Fondaz IRCCS Policlin San Matteo, Unita Epidemiol Clin, Ctr Studio Mielofibrosi, Pavia, Italy

来源：

LEUKEMIA | 2010年 / 24卷 / 08期

关键词：

PROGNOSTIC SCORING SYSTEM; MYELOPROLIFERATIVE NEOPLASMS; CONFERS SUSCEPTIBILITY; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; SURVIVAL; MUTATION; REGARDLESS; INFERIOR; ALLELE;

D O I：

10.1038/leu.2010.126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1533 / 1537

页数：6

共 16 条

[1] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment [J].

Cervantes, Francisco ;

Dupriez, Brigitte ;

Pereira, Arturo ;

Passamonti, Francesco ;

Reilly, John T. ;

Morra, Enrica ;

Vannucchi, Alessandro M. ;

Mesa, Ruben A. ;

Demory, Jean-Loup ;

Barosi, Giovanni ;

Rumi, Elisa ;

Tefferi, Ayalew .

BLOOD, 2009, 113 (13) :2895-2901

[2] Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele [J].

Guglielmelli, Paola ;

Barosi, Giovanni ;

Specchia, Giorgina ;

Rambaldi, Alessandro ;

Lo Coco, Francesco ;

Antonioli, Elisabetta ;

Pieri, Lisa ;

Pancrazzi, Alessandro ;

Ponziani, Vanessa ;

Delaini, Federica ;

Longo, Giovanni ;

Ammatuna, Emanuele ;

Liso, Vincenzo ;

Bosi, Alberto ;

Barbui, Tiziano ;

Vannucchi, Alessandro M. .

BLOOD, 2009, 114 (08) :1477-1483

[3] International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis [J].

Hussein, Kebede ;

Pardanani, Animesh D. ;

Van Dyke, Daniel L. ;

Hanson, Curtis A. ;

Tefferi, Ayalew .

BLOOD, 2010, 115 (03) :496-499

[4] JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms [J].

Jones, Amy V. ;

Chase, Andrew ;

Silver, Richard T. ;

Oscier, David ;

Zoi, Katerina ;

Wang, Y. Lynn ;

Cario, Holger ;

Pahl, Heike L. ;

Collins, Andrew ;

Reiter, Andreas ;

Grand, Francis ;

Cross, Nicholas C. P. .

NATURE GENETICS, 2009, 41 (04) :446-449

[5]

JONES AV, 2010, BLOOD 0319

[6] A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms [J].

Kilpivaara, Outi ;

Mukherjee, Semanti ;

Schram, Alison M. ;

Wadleigh, Martha ;

Mullally, Ann ;

Ebert, Benjamin L. ;

Bass, Adam ;

Marubayashi, Sachie ;

Heguy, Adriana ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop ;

Offit, Kenneth ;

Stone, Richard M. ;

Gilliland, D. Gary ;

Klein, Robert J. ;

Levine, Ross L. .

NATURE GENETICS, 2009, 41 (04) :455-459

[7] The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera [J].

Olcaydu, D. ;

Skoda, R. C. ;

Looser, R. ;

Li, S. ;

Cazzola, M. ;

Pietra, D. ;

Passamonti, F. ;

Lippert, E. ;

Carillo, S. ;

Girodon, F. ;

Vannucchi, A. ;

Reading, N. S. ;

Prchal, J. T. ;

Ay, C. ;

Pabinger, I. ;

Gisslinger, H. ;

Kralovics, R. .

LEUKEMIA, 2009, 23 (10) :1924-1926

[8] A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms [J].

Olcaydu, Damla ;

Harutyunyan, Ashot ;

Jaeger, Roland ;

Berg, Tiina ;

Gisslinger, Bettina ;

Pabinger, Ingrid ;

Gisslinger, Heinz ;

Kralovics, Robert .

NATURE GENETICS, 2009, 41 (04) :450-454

[9] A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction [J].

Pancrazzi, Alessandro ;

Guglielmelli, Paola ;

Ponziani, Vanessa ;

Bergamaschi, Gaetano ;

Bosi, Alberto ;

Barosi, Giovanni ;

Vannucchi, Alessandro M. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (05) :435-441

[10] The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients [J].

Pardanani, A. ;

Lasho, T. L. ;

Finke, C. M. ;

Gangat, N. ;

Wolanskyj, A. P. ;

Hanson, C. A. ;

Tefferi, A. .

LEUKEMIA, 2010, 24 (01) :110-114

← 1 2 →